Across TCGA pan-cancer cohorts, OR2T6 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated OR2T6 data layer compared with 11 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher OR2T6 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated OR2T6 expression acts as an unfavorable survival marker, although some lineages such as LUAD and SKCM show a favorable association.

LUAD, LIHC, and HNSC are the cancer types where OR2T6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.918	0.306	.002	16	view →
LIHC	DFS	Median	III,IV	0.097	0.363	.010	12	view →
HNSC	OS	Median	All	0.242	0.713	.010	6	view →
SKCM	DFS	Median	II,III,IV	0.932	0.675	.018	5	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: OR2T6 tumor-vs-normal RNA expression · all OR2T6 data types